Kategorie: News

The No2 eye care brand in Switzerland and Austria, Similasan has expanded its current portfolio with a range of products developed to specifically treat Blepharitis.

A common eye complaint, Blepharitis is a painful, sometimes ongoing inflammation of the eyelids resulting in burning, redness and swelling.

The new Blepharitis range, comprising Similasan Blephacura and Similasan Tears Again Spray are available in Swiss pharmacies now.

Carla Wullschleger, chief homeopath at Similasan comments: “Around 1 in 20 eye problems reported to healthcare practitioners are related to Blepharitis. Caused by a bacterial infection or skin conditions such as dermatitis, it is usually a long-term condition for which there is no cure. However establishing a daily eye-cleaning routine can help control the symptoms.

“Developed with exceptional natural product ingredients the new Similasan Blepharitis products help to stimulate the body’s natural ability to relieve symptoms.”

Urs Lehmann, CEO of Similasan comments: “The OTC eye care market is buoyant and the sector continues to innovate. Given our heritage in the OTC eye care field it was a natural progression for us to grow the brand within this treatment area.

“We are proud to be present in over 80 per cent of pharmacies and 90 per cent of drug stores in Switzerland meaning we have been able to ensure the product is widely available across the country.”

Swiss based natural product specialist – Similasan – has obtained CE Mark certification for four new eye care products: Similasan Itchy Eye®, Dry Eye®, Pink Eye® and Strained Eye® Drops.

Similasan.gifCurrently the No2 eye care brand in Switzerland and Austria, the CE mark will enable Similasan access to other European markets.

With approved regulatory status as medical devices, this mark indicates that the products meet strict criteria enabling them to be freely distributed and marketed across the EU.

Similasan have now announced plans for an intensive market entry programme for its new eye drop range into Europe and has been working with GBT Pharma, a consultancy specializing in international business development for healthcare brands, to widen their distribution.

Urs Lehmann CEO of Similasan comments: “GBT Pharma’s new market entry programme for our eye drop brands most recently saw the launch into Latin America confirmed. Our market entry programme into Europe is also now well underway.

“GBT Pharma have guided us through the necessary regulatory pathways to achieve this growth and this latest CE mark approval means our popular eye drop products can be freely marketed anywhere in the EU.

“We are actively encouraging companies interested in distribution opportunities to contact the GBT Pharma team at this very exciting stage of the project.”

http://www.gbtpharma.com/contact-us

Swiss pharmaceutical firm, Parsenn Products have announced plans for an intensive market entry programme for the Phytovir brand into Europe and Latin America.

At the same time the company is marking a decade since the launch of its topical cold sore brand – Phytovir – into Swiss pharmacies.

A natural remedy for the treatment of cold sores, Phytovir is clinically proven to be as effective as leading synthetic brands and renowned for its natural anti-viral and wound healing properties.

It is now available in a range of innovative formats, including cream, patches and lipsalve. As a herbal-based product Phytovir is also less likely to create viral resistance compared to synthetic products.

Since its launch in 1975, Parsenn Products has built a respected portfolio of consumer healthcare products into household names.

With widespread distribution across Switzerland and Germany, Parsenn Products have now announced plans for an intensive market entry programme for Phytovir into Europe and Latin America.

To facilitate this growth plan, Parsenn Products has partnered with healthcare specialists GBT Pharma.

Companies interested in bringing the Phytovir brand into their portfolio are invited to contact the GBT Pharma team at this exciting point in the project.